Effects of Anti-IGF1R Antibodies on Tumor Growth Inhibition of 32D higf1r/IRS-1 Xenografts.

Anti-IGF1R antibodies were administered IP twice per week at 100 or 300 µg/dose for the duration of the experiment. TGI was calculated on the last day of each study and expressed relative to the initial and final mean tumor volume of the control group. The significance of TGI against the control group was calculated using RMANOVA followed by a post-hoc Scheffe’s test. Serum samples were collected 2 hours after the last antibody dose (n = 3). TGI for Mab 391 is the mean and standard deviation of 4 xenograft experiments. *All TGI values were significant against the control IgG1 group, p<0.05. NA: not available.